Belite Bio Inc (NAS:BLTE)

Q4 2025 Belite Bio Inc Earnings Call Transcript

Mar 2, 2026 / 09:30 PM GMT

Release Date Price: $177.58 (-6.68%)

Transcript

Key Points

Positve

Belite Bio Inc (BLTE) achieved significant progress in 2025, including the announcement of topline results for the Phase 3 Dragon trial, which met its primary endpoint.
The company successfully completed a $402 million public offering, strengthening its financial position for commercialization and pipeline development.
Belite Bio Inc (BLTE) plans to submit an NDA to the FDA in Q2 2026, marking a significant step towards commercialization.
The company has hired key leadership positions and is building its organization in preparation for the commercialization of its Stargardt disease treatment.
Belite Bio Inc (BLTE) closed the year with $772.6 million in cash equivalents, providing a strong financial foundation for future objectives.

Negative

R&D expenses increased significantly to $14.6 million in Q4 2025 compared to $7.3 million in Q4 2024, primarily due to trial-related expenses.
The company reported a net loss of $25.3 million for Q4 2025, compared to $10.1 million in Q4 2024, indicating increased financial pressure.
SG&A expenses rose to $13.5 million in Q4 2025 from $4.2 million in Q4 2024, driven by share-based compensation and professional service fees.
The full-year net loss for 2025 was $77.6 million, a significant increase from $36.1 million in 2024, reflecting higher operational costs.
The commercialization and budget for the next few years are expected to cost between $200 to $150 million, indicating substantial future financial commitments.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BLTE.OQ - Belite Bio Inc
Q4 2025 Belite Bio Inc Earnings Call
Mar 02, 2026 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for joining us and welcome to the B Light Bio 4th quarter and fiscal year end 2025 earnings call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please raise your hand. If you have dialed into today's call, please press 9 to raise your hand and 6 to unmute. I will now hand the conference over to Sophie Hunt. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon, everyone.

Thank you for joining us. On the call today are Dr. Tom Linn, Chairman and CEO of B Light

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.